The recent review article, “Evolving Understanding of the Causes of Pneumonia in Adults, With Special Attention to the Role of Pneumococcus” in the November 15, 2017 Clinical Infectious Diseases, addresses the trends and current status of the etiology of Community Acquired Pneumonia (CAP). These data support the need for a pathogen-agnostic/host-based approach to the disease, such as BioAegis’ plasma gelsolin program. Three of the most recent studies, including the CDC’s EPIC Study published in July 2015 New England Journal of Medicine, underscore the failure to identify a causative pathogen in greater than 50% of the cases. Streptococcus pneumoniae remains the most commonly identified pathogen, although it is demonstrated in <20% of cases. Numerous other gram-positive and gram-negative bacteria are less frequently recovered. Viruses are found in 25% of the patients, either alone or as a coinfection. These findings have implications for antibiotic stewardship and strongly reinforce the need for a host-based approach to this disease as a whole.
- April, 2019: BioAegis Therapeutics Receives US Patent Protection for the Therapeutic Uses of Plasma Gelsolin in Renal Failure
- March 2019: BioAegis Therapeutics Completes Enrollment in its Phase 1b/2a Dose-Ranging Safety Study of Recombinant Plasma Gelsolin for Community-Acquired Pneumonia
- March, 2019: BioAegis Therapeutics Awarded European Patent Protection for the Uses of Plasma Gelsolin to Treat Infections
- February 2019: BioAegis Therapeutics Expands Phase 1b/2a Community- Acquired Pneumonia Study to the Republic of Georgia — Successfully Completes Second of Four Dosing Cohorts
- February 2019: BioAegis Therapeutics Announces Publication in “Clinical Infectious Diseases” Linking Depleted Plasma Gelsolin Concentrations at Admission to Severe Pneumonia Outcomes in CDC-Sponsored “Etiology of Pneumonia in the Community (EPIC)” Study